$CDLX

Cardlytics Second Quarter 2026 Financial Results Driven By Strong Operational Performance

Cardlytics, Inc. (CDLX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cardlytics Second Quarter 2026 Financial Results Driven By Strong Operational Performance • Company delivers strong second quarter results: ◦ Revenues of $36.9 million ◦ Billings of $65.5 million ◦ Adjusted Contribution of $21.3 million ◦ Net Loss of $(14.9) million

Original reporting
Published Aug 5, 2026, 8:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 5, 2026, 8:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CDLX
Neutral
medium confidence
Mentioned
$CDLX
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CDLXNeutralMed
01

Why it matters

Traders can update near-term expectations using the disclosed Q3 guidance bands and assess whether the margin improvement narrative offsets continued YoY declines in revenue, billings, users, and cash flow.

02

Market read

Fresh quarterly metrics plus explicit Q3 guidance create a tradable setup into and during the earnings webcast.

03

What to watch

MQUs fell 17% YoY and ACPU declined, so the key question is whether Q3 guidance implies stabilization in unit economics or continued top-line shrinkage.

Relevance 7/10Novelty 8/10Timing: after-hours/earnings call today, Aug 5, 2026 at 5:00 PM ET

Background

This is an SEC Form 8-K with Exhibit 99.1 covering Cardlytics’ Q2 2026 financial results and Q3 2026 guidance ranges.

Company-level read

Ticker impact

$CDLXNeutralMedium confidence
Context

Cardlytics reported Q2 2026 results and provided Q3 2026 guidance ranges for Billings, Revenue, Adjusted Contribution, and Adjusted EBITDA.

Expected impact

Likely modest volatility around the earnings call and any market reaction to the guidance ranges versus expectations, with downside risk if investors focus on worsening net loss and cash burn.

Evidence & confidence

The filing discloses fresh quarterly datapoints (revenue, billings, net loss, FCF) plus explicit Q3 guidance ranges, which can drive repricing even without a beat/raise narrative.

Market effects

Signals ongoing pressure on purchase-intelligence monetization (declining billings, users) while emphasizing margin improvement and self-sustainability efforts.

No specific regional read-through beyond US and UK platform operations mentioned.

Limited global impact; primarily a US-listed ad-tech/purchase-intelligence name with UK exposure.

Counterpoint

Investors may discount the “within guidance” framing and focus on worsening net loss, operating cash outflow, and free cash flow deterioration versus the prior year.

Key entities

  • Cardlytics, Inc.

    Purchase intelligence platform reporting Q2 2026 results and issuing Q3 2026 guidance ranges.

  • Amit Gupta

    CEO quoted on execution translating into results and being within guidance across key metrics.

  • David Evans

    CFO quoted on sequential growth and self-sustainability plan.

Related articles

$CDLXMedAI 8/10

Cardlytics (CDLX) Q2 2026 Earnings Call Transcript

Cardlytics (CDLX) reported Q2 2026 results on an earnings call. Revenue was $36.9M, down 36% YoY, with billings $65.5M (-34%) and adjusted contribution $21.3M (-32%). Net loss was $14.9M. Q3 2026 guidance: billings $61M-$67M, revenue $34M-$39M, adjusted EBITDA $0M-$3M. Cash was $28M.

$CDLXMedAI 8/10

Cardlytics: Q2 Earnings Snapshot

Cardlytics (CDLX) reported a Q2 loss of $14.9 million, or $2.58 per share. Adjusted for discontinued operations, the loss was $1.50 per share. Revenue was $36.9 million. For the quarter ending September, the company expects revenue of $34 million to $39 million.

$INFYHighAI 8/10

Infosys Ltd (INFY) (Q2 2027) Earnings Call Highlights: AI Revenue Surges 29%

Infosys reported Q2 2027 revenue growth of 1.5% YoY and 1.2% sequentially, below expectations. AI revenue surged 29% QoQ. The company revised full-year guidance to 1-2% growth due to pricing pressure, cautious client spending, and softness in high-tech and retail sectors. CEO Salil Parekh expressed confidence in organic growth recovery for FY28, citing a $2B+ mega deal and strong AI traction.

$SLGMed

SL Green Realty Corp (SLG) (Q3 2026) Earnings Call Highlights: 95% Leased Occupancy

SL Green Realty Corp (SLG) reported 95% leased occupancy and raised guidance. The company has a leasing pipeline exceeding 1.3M sq ft, with mark-to-market above 20%. Higher interest rates impacted guidance by $0.25, with $0.05 from fee income and the rest from interest expense. Cap rates are expected to stay around 5-6%, with strong rent growth. Development opportunities are modeled at $240-$270 per sq ft.

$YARIYMed

Yara International ASA (YARIY) (Q3 2026) Earnings Call Highlights: EBITDA Slips to $675

Yara International ASA (YARIY) reported Q3 2026 EBITDA of $675 million, down from $804 million YoY, due to higher European gas costs and lower volumes. The company curtailed 270,000 tons of ammonia production and faced demand slowdowns, particularly in Latin America. Management discussed gas cost impacts, production curtailments, and market demand trends during the earnings call.